Extracellular vesicle bioactivity and potential for clinical development are determined by mesenchymal stromal cell clonal subtype
EVs released by closely related MSC subtypes within the same heterogeneous population differ significantly in terms of cargo abundance, bioactivity, and pre-clinical in vivo efficacy. Analysis of defined EV subsets will aid mechanistic understanding and prioritisation for EV therapeutics.
Authors
- Chris MacDonald (ORCID: https://orcid.org/0000-0002-7450-600X)
- Andrew P. Stone (ORCID: https://orcid.org/0000-0002-1087-9923)
- Xiaonong Wang
- Emma Rand (ORCID: https://orcid.org/0000-0002-1358-8275)
- Rachel E. Crossland (ORCID: https://orcid.org/0000-0001-6138-160X)
- Tony R. Larson (ORCID: https://orcid.org/0000-0003-1337-3482)
- Paul G. Genever (ORCID: https://orcid.org/0000-0002-5730-8976)
- David A. Mentlak (ORCID: https://orcid.org/0000-0002-4212-5552)
- Oksana Kehoe (ORCID: https://orcid.org/0000-0002-8702-275X)
- Alasdair G. Kay (ORCID: https://orcid.org/0000-0003-1953-331X)
- Samuel Elberfeld
- Savvas Ioannou (ORCID: https://orcid.org/0000-0001-7949-8339)
- William Bolton
Institutions
- Robert Jones and Agnes Hunt Orthopaedic Hospital (GB)
- University of York (GB)
- Keele University (GB)
- Newcastle University (GB)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s13287-025-04665-z
- Citations
- 2
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Wellcome Trust
- Yorkshire Forward
- Versus Arthritis
- Directorate for Biological Sciences
- Medical Research Council
- Engineering and Physical Sciences Research Council